Good
Mostly Aligned
Patient Risk:
Low
Summary
The AI claims generally align with labeling-level facts that JEMPERLI (dostarlimab-gxly) is an anti-cancer monoclonal antibody and is administered as an IV infusion by healthcare professionals. However, the claims about indications are overly vague and do not reflect the label’s specific approved patient populations/criteria, which is a material accuracy gap for “used to treat certain patients with specific cancer types.”
Category Scores
Accurate Statements
Jemperli is a cancer medicine (dostarlimab).
Label describes JEMPERLI (dostarlimab-gxly) indications for endometrial cancer and dMMR recurrent/advanced solid tumors (Sections 1.1 and 1.2).
Jemperli is administered by healthcare professionals.
Label dosage form states “Injection … for intravenous infusion after dilution” (Section 3), consistent with administration requiring infusion preparation/clinical administration context; no direct wording about “healthcare professionals” is provided, but the IV infusion after dilution is label-consistent.
Jemperli is generally administered as an intravenous infusion.
Dosage form: “for intravenous infusion after dilution” (Section 3).
Unsupported Statements
Jemperli is used to treat certain patients with specific cancer types.
The label specifies precise labeled indications and patient selection criteria (e.g., adult patients with primary advanced/recurrent EC in combination regimen; adult dMMR recurrent/advanced EC after platinum and not candidates for curative surgery/radiation; adult dMMR recurrent/advanced solid tumors with progression and no satisfactory alternative treatments) (Sections 1.1, 1.2, and 2.1). The statement is too general to confirm alignment with the label’s specific populations/criteria.
The exact approved uses of Jemperli depend on the country and the specific indication granted by regulators.
Label provided is FDA-specific and does not state that approvals vary by country or regulators.
Contradictions
Important Omissions
If discussing approved use/indication, the label requires specification of the labeled cancer types and criteria (e.g., dMMR status determined by an FDA-approved test; progression after platinum-containing regimen for EC single-agent indication; not candidates for curative surgery/radiation for that EC indication; for solid tumors: progression after prior treatment and no satisfactory alternative options).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
No contraindications, dosing regimen, or specific safety instructions were claimed beyond general IV infusion administration and non-specific indication wording.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Indication-related claims are overly vague and do not reflect the FDA label’s specific labeled indications and patient-selection criteria.
Suggested Improvement
Replace general statements with the label’s specified populations/criteria, including dMMR determination by an FDA-approved test and the relevant disease/setting requirements (EC vs dMMR recurrent/advanced solid tumors).